The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials

被引：12
|
作者：
Peyrin-Biroulet, Laurent [1 ,2 ]
Gower-Rousseau, Corinne [3 ,4 ,5 ]
机构：
[1] Univ Lorraine, INSERM U954, Allee Morvan, F-54511 Vandoeuvre Les Nancy, France
[2] Univ Lorraine, Dept Hepatogastroenterol, Allee Morvan, F-54511 Vandoeuvre Les Nancy, France
[3] Univ Hosp, EPIMAD Registry, Publ Hlth Epidemiol & Econ Hlth, Reg House Clin Res, F-59000 Lille, France
[4] Univ Hosp, INSERM, UMR 995, Int Ctr Inflammat Res LIRIC, F-59000 Lille, France
[5] IBD & Environm Factors Epidemiol & Funct Anal Grp, F-59000 Lille, France
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷 / 12期
关键词：
QUALITY-OF-LIFE; INTERNATIONAL CLASSIFICATION; VALIDATION; DISEASE;
D O I：
10.1093/ecco-jcc/jjw156
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1375 / 1377
页数：3
相关论文
共 50 条
  • [1] Social functioning - Should it become an endpoint in trials of antidepressants?
    Bech, P
    CNS DRUGS, 2005, 19 (04) : 313 - 324
  • [2] Clinical trials of biosimilars should become more similar
    Kay, Jonathan
    Isaacs, John D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 4 - 6
  • [3] From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD? Comment
    Stidham, Ryan William
    Vickers, Andrew
    Singh, Karandeep
    Waljee, Akbar K.
    GUT, 2022, 71 (06) : 1046 - +
  • [4] Should clinical trials about prostate cancer assess the frailty as an endpoint?
    Irfan Karahan
    Didem Sener Dede
    International Urology and Nephrology, 2023, 55 : 1729 - 1730
  • [5] Should clinical trials about prostate cancer assess the frailty as an endpoint?
    Karahan, Irfan
    Dede, Didem Sener
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (07) : 1729 - 1730
  • [6] MUNE as an endpoint in clinical trials
    Bryan, WW
    MOTOR UNIT NUMBER ESTIMATION (MUNE), PROCEEDINGS, 2003, 55 : 324 - 328
  • [7] Should Cystatin C eGFR Become Routine Clinical Practice?
    Spencer, Sebastian
    Desborough, Robert
    Bhandari, Sunil
    BIOMOLECULES, 2023, 13 (07)
  • [8] Endpoint considerations for clinical trials
    Walton, MK
    AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2002, 3 : S3 - S6
  • [9] N-of-1 clinical trials should be incorporated into clinical practice
    Berlin, Jesse A.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (12) : 1283 - 1284
  • [10] Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE
    Kalunian, Kenneth C.
    Urowitz, Murray
    Isenberg, David A.
    Merrill, Joan T.
    Petri, Michelle
    Furie, Richard
    Morgan-Cox, MaryAnn
    Taha, Rebecca
    Silk, Maria
    Linnik, Matthew D.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345